Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

557 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Selective MCL-1 inhibitor ABBV-467 is efficacious in tumor models but is associated with cardiac troponin increases in patients.
Yuda J, Will C, Phillips DC, Abraham L, Alvey C, Avigdor A, Buck W, Besenhofer L, Boghaert E, Cheng D, Cojocari D, Doyle K, Hansen TM, Huang K, Johnson EF, Judd AS, Judge RA, Kalvass JC, Kunzer A, Lam LT, Li R, Martin RL, Mastracchio A, Mitten M, Petrich A, Wang J, Ward JE, Zhang H, Wang X, Wolff JE, Bell-McGuinn KM, Souers AJ. Yuda J, et al. Among authors: doyle k. Commun Med (Lond). 2023 Oct 25;3(1):154. doi: 10.1038/s43856-023-00380-z. Commun Med (Lond). 2023. PMID: 37880389 Free PMC article.
Genetic Biomarkers Of Sensitivity and Resistance to Venetoclax Monotherapy in Patients With Relapsed Acute Myeloid Leukemia.
Chyla B, Daver N, Doyle K, McKeegan E, Huang X, Ruvolo V, Wang Z, Chen K, Souers A, Leverson J, Potluri J, Boghaert E, Bhathena A, Konopleva M, Popovic R. Chyla B, et al. Among authors: doyle k. Am J Hematol. 2018 May 17;93(8):E202-5. doi: 10.1002/ajh.25146. Online ahead of print. Am J Hematol. 2018. PMID: 29770480 Free PMC article. No abstract available.
A-306989, an inhibitor of adenosine kinase, is renoprotective in rodent models of podocyte, basement membrane, and obstructive injury.
Zhu CZ, Gopalakrishnan S, Doyle K, Nikkel AL, Olson L, Abraham VC, Leys L, Widomski D, Salte K, Putman B, Pratt S, Ma J, Su Z, Gopalakrishnan M, Lee CH, McGaraughty SP. Zhu CZ, et al. Among authors: doyle k. Eur J Pharmacol. 2016 Oct 5;788:1-11. doi: 10.1016/j.ejphar.2016.06.012. Epub 2016 Jun 8. Eur J Pharmacol. 2016. PMID: 27288879
Targeting Anti-TGF-β Therapy to Fibrotic Kidneys with a Dual Specificity Antibody Approach.
McGaraughty S, Davis-Taber RA, Zhu CZ, Cole TB, Nikkel AL, Chhaya M, Doyle KJ, Olson LM, Preston GM, Grinnell CM, Salte KM, Giamis AM, Luo Y, Sun V, Goodearl AD, Gopalakrishnan M, Lacy SE. McGaraughty S, et al. J Am Soc Nephrol. 2017 Dec;28(12):3616-3626. doi: 10.1681/ASN.2017010013. Epub 2017 Aug 21. J Am Soc Nephrol. 2017. PMID: 28827403 Free PMC article.
A summary of the 2023 Society of Obstetric Medicine of Australia and New Zealand (SOMANZ) hypertension in pregnancy guideline.
Shanmugalingam R, Barrett HL, Beech A, Bowyer L, Crozier T, Davidson A, Dekker Nitert M, Doyle K, Grzeskowiak L, Hall N, Cheikh Hassan HI, Hennessy A, Henry A, Langsford D, Lee VW, Munn Z, Peek MJ, Said JM, Tanner H, Taylor R, Ward M, Waugh J, Yen LL, Medcalf E, Bell KJ, Ackermann D, Turner R, Makris A. Shanmugalingam R, et al. Among authors: doyle k. Med J Aust. 2024 May 19. doi: 10.5694/mja2.52312. Online ahead of print. Med J Aust. 2024. PMID: 38763516
Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial.
Parker CC, Clarke NW, Cook AD, Kynaston H, Catton CN, Cross WR, Petersen PM, Persad RA, Saad F, Bower LC, Logue J, Payne H, Forcat S, Goldstein C, Murphy C, Anderson J, Barkati M, Bottomley DM, Branagan J, Choudhury A, Chung PWM, Cogley L, Goh CL, Hoskin P, Khoo V, Malone SC, Masters L, Morris SL, Nabid A, Ong AD, Raman R, Tarver KL, Tree AC, Worlding J, Wylie JP, Zarkar AM, Parulekar WR, Parmar MKB, Sydes MR; RADICALS investigators. Parker CC, et al. Lancet. 2024 Jun 1;403(10442):2405-2415. doi: 10.1016/S0140-6736(24)00548-8. Epub 2024 May 16. Lancet. 2024. PMID: 38763154 Free article. Clinical Trial.
Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial.
Parker CC, Kynaston H, Cook AD, Clarke NW, Catton CN, Cross WR, Petersen PM, Persad RA, Pugh CA, Saad F, Logue J, Payne H, Bower LC, Brawley C, Rauchenberger M, Barkati M, Bottomley DM, Brasso K, Chung HT, Chung PWM, Conroy R, Falconer A, Ford V, Goh CL, Heath CM, James ND, Kim-Sing C, Kodavatiganti R, Malone SC, Morris SL, Nabid A, Ong AD, Raman R, Rodda S, Wells P, Worlding J, Parulekar WR, Parmar MKB, Sydes MR; RADICALS investigators. Parker CC, et al. Lancet. 2024 Jun 1;403(10442):2416-2425. doi: 10.1016/S0140-6736(24)00549-X. Epub 2024 May 16. Lancet. 2024. PMID: 38763153 Free article. Clinical Trial.
557 results